Abstract：Objective To explore the efficacy of vonoprazan in the treatment of severe reflux esophagitis (RE) and its effects on gastrin and inflammatory factors.Methods Sixty-two patients who were diagnosed with severe RE in the gastroenterology clinic of Anhui Provincial Corps Hospital of Chinese People's Armed Police Force from February 2021 to February 2022 were selected and randomly divided into two groups: vonoprazan group (31 cases) and control group (31 cases).The vonoprazan group was treated with vonoprazan and Itopride,while the control group with rabeprazole and itopride. Post-treatment clinical response rate was compared between the two groups, as well as the endoscopic scores, gastrin, TNF(tumor necrosis factor), and IL-6(Interleukin-6) before and after the treatment.Results The effective rate of the vonoprazan group was 87.10%, which was significantly higher than that of the control group (64.52%) (χ2=4.309, P<0.05). After treatment, both endoscopic scores (0.30±0.13, 0.64±0.26) were significantly lower than those before treatment (3.42±0.51, 3.38±0.48) and improved more significantly in the vonoprazan group (t=-6.51, P<0.01). The level of gastrin in vonoprazan group [(88.93±11.37) pg/ml] were significantly higher than that of the control group [(60.78±7.98) pg/ml], while the levels of TNF [(5.95±0.68) pg/ml] and IL-6 [(5.55±0.67) pg/ml] were significantly lower than those in the control group[(7.88±0.99)pg/ml,(8.24±0.92)pg/ml], and the differences were all statistically significant (P<0.01). Both groups had one adverse reaction (3.23%).Conclusions Vonoprazan in the treatment of severe RE can significantly improve the efficiency, repair the damaged gastric mucosa, and significantly adjust the serum gastrin and inflammatory factor levels without increasing the adverse effects.
洪丽莉. 伏诺拉生治疗重症反流性食管炎的疗效及其对胃泌素和炎症因子的影响[J]. 武警医学, 2022, 33(12): 1062-1064.
HONG Lili. Efficacy of vonoprazan in treatment of severe reflux esophagitis and its effects on gastrin and inflammatory factors. Med. J. Chin. Peop. Armed Poli. Forc., 2022, 33(12): 1062-1064.
Xiao Y,Zhang S,Dai N,et al. Phase Ⅲ, randomised, doubleblind,multicentre study to evaluate the efficacy and safety of vonoprazan compared with lansoprazole in Asian patients with erosive oesophagitis[J]. Gut, 2020, 69(2): 224-230.
[11]
Jenkins H,Sakurai Y,Nishimura A,et al.Randomised clinical trial:safety,tolerability,pharmacokinetics and pharmacodynamics of repeated doses of TAK-438(vonoprazan),a novel potassium-competitive acid blocker,in healthy male subjects[J].Aliment Pharmacol Ther, 2015,41(7):636-648.
2022, Vol. 33 
